Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.64 |
| ▸ | DDB1 | Q16531 | 13/20 | 0.64 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20133114 | 0.91 | CRBN (0.58) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL20133175 | 0.90 | CRBN (0.57) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL20133102 | 0.89 | CRBN (0.56) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL20133129 | 0.86 | CRBN (0.54) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL25235240 | 0.85 | CRBN (0.62) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL30423089 | 0.85 | CRBN (0.62) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL20294714 | 0.85 | CRBN (0.62) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL20759719 | 0.85 | CRBN (0.65) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL20121022 | 0.85 | CRBN (0.54) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL29058457 | 0.85 | CRBN (0.56) | CRBNDDB1IKZF3ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20210047267-A1 | THALIDOMIDE ANALOGS AND METHODS OF USE | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-18 | — | — | US | disclosed |
| US-10836721-B2 | Thalidomide analogs and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200325102-A1 | THALIDOMIDE ANALOGS AND METHODS OF USE | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-10-15 | — | — | US | disclosed |
| US-10730835-B2 | Thalidomide analogs and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, HEALTH AND HUMAN SERVICES (US) | 2020-08-04 | — | — | US | disclosed |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | CRBN 3/4885DDB1 750/4885IKZF3 3015/4885 |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | CRBN 3/4885DDB1 746/4885IKZF3 3010/4885 |
| US-10836721-B2 | Thalidomide analogs and methods of use | PGF, TYMP, TPMT | CRBN 233/4885DDB1 466/4885IKZF3 424/4885 |
| US-10730835-B2 | Thalidomide analogs and methods of use | PGF, TYMP, TPMT | CRBN 233/4885DDB1 466/4885IKZF3 424/4885 |
| US-20210047267-A1 | THALIDOMIDE ANALOGS AND METHODS OF USE | PGF, TYMP, TPMT | CRBN 233/4885DDB1 466/4885IKZF3 424/4885 |
| US-20200325102-A1 | THALIDOMIDE ANALOGS AND METHODS OF USE | PGF, TYMP, TPMT | CRBN 233/4885DDB1 466/4885IKZF3 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.